Expand INKT Menu
INKT MENU

INKT Latest Press Releases

-- November 20, 2025 --

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors Globe Newswire 11:42 AM

-- November 14, 2025 --

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation Globe Newswire 7:30 AM

-- November 7, 2025 --

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 Globe Newswire 9:00 AM

-- November 5, 2025 --

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development Globe Newswire 9:07 AM

-- October 30, 2025 --

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Globe Newswire 9:00 AM

-- September 29, 2025 --

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors Globe Newswire 7:30 AM

-- September 25, 2025 --

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA Globe Newswire 7:30 AM

-- September 18, 2025 --

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development Globe Newswire 7:30 AM

-- August 14, 2025 --

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results Globe Newswire 7:30 AM

-- July 31, 2025 --

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes